Cutaneous melanoma
MONDO:0005012A primary melanoma arising from atypical melanocytes in the skin. Precursor lesions include acquired and congenital melanocytic nevi, and dysplastic nevi. Several histologic variants have been recognized, including superficial spreading melanoma, acral lentiginous melanoma, nodular melanoma, and lentigo maligna melanoma.
Also known as: cutaneous (skin) melanoma, cutaneous melanoma, cutaneous melanoma (disease), malignant cutaneous melanoma, malignant melanoma (of skin), stage unspecified, malignant melanoma of skin, malignant melanoma of skin stage unspecified, melanoma (disease) of zone of skin
3023 clinical trials for this condition and its sub-types, 273 tagged with Cutaneous melanoma itself.
Follow this condition to get notified about new trialsWhere it sits in the disease tree
Browse by category →Sub-types of Cutaneous melanoma
-
Acral lentiginous melanoma 17 trials
-
Lentigo maligna melanoma 4 trials
-
Spitzoid melanoma 3 trials
-
Balloon cell malignant melanoma 1 trial
-
Desmoplastic melanoma 1 trial
-
Nodular malignant melanoma 1 trial
-
Superficial spreading melanoma 1 trial
-
Amelanotic skin melanoma 0 trials
-
Eyelid melanoma 0 trials
-
Can a smaller dose of this cancer drug still work? new trial aims to find out
Disease control Not yet recruitingThis phase 2 trial is testing whether a lower dose of the immunotherapy drug nivolumab, given less often, can still control cancer in people with various advanced or metastatic cancers. The goal is to see if a cheaper, more accessible regimen works as well as the standard high-co…
Phase 2 • Sponsor: Fred Hutchinson Cancer Center • Aim: Disease control
Last updated Sep 19, 2026 00:00 UTC
-
New drug combo aims to shrink melanoma before surgery
Disease control Not yet recruitingThis study tests whether giving two immunotherapy drugs (fianlimab and cemiplimab) before surgery can shrink melanoma tumors in people with stage IIIB to IV melanoma. About 35 adults will receive the drugs, then have surgery to remove any remaining cancer. The main goal is to see…
Phase 2 • Sponsor: University of California, Irvine • Aim: Disease control
Last updated Sep 13, 2026 00:00 UTC
-
Liver-Targeted immune cell attack tested against melanoma spread
Disease control Not yet recruitingResearchers are testing a treatment for melanoma that has spread to the liver. They collect tumor-infiltrating lymphocytes, a type of immune cell, from the patient's own tumor and grow them in the lab. Before returning the cells, they use a technique called percutaneous hepatic p…
Phase 1 • Sponsor: Vastra Gotaland Region • Aim: Disease control
Last updated Sep 11, 2026 00:00 UTC
-
Can a DNA repair gene flaw make melanoma vulnerable to chemotherapy?
Disease control Not yet recruitingThis phase II trial tests whether the chemotherapy drug temozolomide can shrink tumors in people with advanced or metastatic melanoma that has a mutation in the BAP1 gene. BAP1 normally helps repair damaged DNA, and when it is faulty, cancer cells may become more sensitive to cer…
Phase 2 • Sponsor: Assistance Publique Hopitaux De Marseille • Aim: Disease control
Last updated Sep 10, 2026 00:00 UTC
-
Can a short Pre-Surgery immunotherapy course replace Long-Term adjuvant treatment for melanoma?
Disease control Not yet recruitingThis phase 2 trial is investigating whether giving immunotherapy before surgery for advanced melanoma (stage IIIB to IV M1a) can maintain survival while allowing patients to skip the usual adjuvant therapy after surgery. Participants are randomly assigned to receive either two in…
Phase 2 • Sponsor: UNC Lineberger Comprehensive Cancer Center • Aim: Disease control
Last updated Aug 07, 2026 00:00 UTC
-
Blood test may let cancer patients take safe breaks from immunotherapy
Disease control Not yet recruitingThis trial investigates whether a sensitive blood test (Signatera) can detect when it is safe to pause immunotherapy in people with advanced solid tumors like lung cancer, melanoma, and colorectal cancer. Participants are randomly assigned to either continuous standard immunother…
Sponsor: Natera, Inc. • Aim: Disease control
Last updated Aug 06, 2026 00:00 UTC
-
Could a Gut-Focused drug revive immunotherapy for tough melanomas?
Disease control Not yet recruitingThis study tests whether adding axelopran, a drug that blocks opioid side effects in the gut, to the immunotherapy nivolumab can help people with advanced melanoma that no longer responds to PD-1 inhibitors. The trial includes about 28 adults with unresectable or metastatic cutan…
Phase 1/2 • Sponsor: John Kirkwood • Aim: Disease control
Last updated Jul 15, 2026 00:00 UTC
-
New keytruda copycat tested in melanoma patients after surgery
Disease control Not yet recruitingThis study tests a new drug called Bmab1800 to see if it works like the approved drug Keytruda in people with stage IIB, IIC, or III melanoma after their tumor has been removed by surgery. About 138 adults will get either Bmab1800 or Keytruda, and researchers will compare how the…
Phase 1 • Sponsor: Biocon Biologics UK PLC • Aim: Disease control
Last updated Jun 27, 2026 12:33 UTC
-
Triple drug attack on melanoma: new trial hopes to boost surgery success
Disease control Not yet recruitingThis phase 2 trial tests three immune-boosting drugs (cemiplimab, fianlimab, and ipilimumab) given before surgery in 20 people with advanced but removable melanoma. The goal is to see if the combination is safe and can shrink tumors, potentially improving outcomes. Participants m…
Phase 2 • Sponsor: M.D. Anderson Cancer Center • Aim: Disease control
Last updated Jun 27, 2026 12:04 UTC
-
Experimental cell therapy takes on Drug-Resistant melanoma
Disease control Not yet recruitingThis Phase 2 trial tests a new cell therapy called RAPA-201 for people with advanced melanoma that has stopped responding to PD-(L)1 inhibitors. The therapy uses a patient's own immune cells, modified to resist the drug rapamycin, and is given along with chemotherapy. The study a…
Phase 2 • Sponsor: Rapa Therapeutics LLC • Aim: Disease control
Last updated Jun 27, 2026 11:03 UTC
-
Personalized cell therapy takes on advanced melanoma in new trial
Disease control Not yet recruitingThis Phase 2 trial tests whether a personalized cell therapy called HS-IT101 works better than chemotherapy for people with advanced melanoma that has stopped responding to standard treatments. HS-IT101 uses a patient's own immune cells, grown in large numbers in a lab, to fight …
Phase 2 • Sponsor: Qingdao Sino-Cell Biomedicine Co., Ltd. • Aim: Disease control
Last updated Jun 27, 2026 09:05 UTC
-
Magnetic tracer could replace radioactive dye in melanoma surgery
Diagnosis Not yet recruitingThis phase 3 trial tests whether a magnetic tracer (Magtrace) works as well as the standard radioactive dye plus blue dye for finding sentinel lymph nodes in people with melanoma. About 254 adults having surgery for melanoma will receive both tracers and be randomly assigned to h…
Phase 3 • Sponsor: Vastra Gotaland Region • Aim: Diagnosis
Last updated Sep 05, 2026 00:00 UTC
-
Can morning light boost melanoma treatment? new trial tests simple iPad therapy
Symptom relief Not yet recruitingThis early-phase trial tests whether a home-based morning light therapy program can help people with advanced melanoma who are receiving tumor-infiltrating lymphocyte (TIL) therapy. The light therapy is delivered through an iPad app and aims to improve the body's natural sleep-wa…
Phase 1 • Sponsor: City of Hope Medical Center • Aim: Symptom relief
Last updated Jun 27, 2026 13:02 UTC
-
Your gut bacteria may hold the key to whether immunotherapy works
Knowledge-focused Not yet recruitingResearchers are studying whether the mix of bacteria in a person's gut can predict how well they respond to immunotherapy drugs called immune checkpoint inhibitors. The trial enrolls about 360 adults with advanced non-small cell lung cancer, melanoma, endometrial cancer, or cervi…
Sponsor: European Institute of Oncology • Aim: Knowledge-focused
Last updated Sep 13, 2026 00:00 UTC
-
Can a simple paper tool help melanoma patients make tough biopsy decisions?
Knowledge-focused Not yet recruitingThis study tests a paper-based decision aid designed to help people with intermediate-risk melanoma decide whether to have a sentinel lymph node biopsy. The tool provides clear information about the procedure, its risks and benefits, and helps patients think about their personal …
Sponsor: University of Virginia • Aim: Knowledge-focused
Last updated Jun 27, 2026 14:00 UTC
-
Could skipping a lymph node test be just as good for older melanoma patients?
Knowledge-focused Not yet recruitingThis study looks at whether older adults (75+) with early-stage melanoma can safely skip an extra lymph node biopsy after their main surgery. The goal is to see if the simpler surgery alone works just as well and improves overall well-being. About 428 participants will be followe…
Phase 3 • Sponsor: Eastern Cooperative Oncology Group • Aim: Knowledge-focused
Last updated Jun 27, 2026 07:57 UTC